Direct-acting antiviral treatment of acute hepatitis C virus infections

References

• Global Hepatitis Report 2017 [Internet]. Geneva (Switzerland): World Health Organization; Apr 2017 [cited 2018 Mar 12]. Available from: http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1
   Google Scholar
• Mohamed AA, Elbedewy TA, El-Serafy M, et al. Hepatitis C virus: A global view. World J Hepatol. 2015;7(26):2676.
   PubMed Web of Science ®Google Scholar
• Kim DY. Estimation of direct medical costs related to chronic hepatitis C: a rationale for early antiviral therapy. Gut and Liver. 2017 Nov 15;11(6):745–746. PubMed PMID: 29081211; PubMed Central PMCID: PMCPMC5669589. eng.
   PubMed Web of Science ®Google Scholar
• AASLD-ISDA. Management of Acute HCV Infection. Recommendations for testing, managing, and treating hepatitis C. Alexandria (VA): American Association for the Study of Liver Diseases; 2018 Mar 10 [cited 2017 Sept 21]. Available from: https://www.hcvguidelines.org/unique-populations/acute-infection
   Google Scholar
• Polaris Observatory HCV Collaborators. et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161–176. PubMed PMID: 28404132; eng.
   PubMed Web of Science ®Google Scholar
• Woode ME, Abu-Zaineh M, Perriens J, et al. Potential market size and impact of hepatitis C treatment in low- and middle-income countries. J Viral Hepat. 2016 Jul;23(7):522–534. PubMed PMID: 26924428; eng.
   PubMed Web of Science ®Google Scholar
• Pepin J, Abou Chakra CN, Pepin E, et al. Evolution of the global burden of viral infections from unsafe medical injections, 2000-2010. PloS One. 2014;9(6):e99677. PubMed PMID: 24911341; PubMed Central PMCID: PMCPMC4049770.
   PubMed Web of Science ®Google Scholar
• Graham CS, Swan T. A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res. 2015 Jul;119:89–96. PubMed PMID: 25615583.
   PubMed Web of Science ®Google Scholar
• Hullegie SJ, Arends JE, Rijnders BJ, et al. Current knowledge and future perspectives on acute hepatitis C infection. Clin Microbiol Infect. 2015 Aug;21(8):797.e9-797.e17. PubMed PMID: 25892133; eng.
   PubMed Web of Science ®Google Scholar
• O’Keefe D, Stoove M, Doyle J, et al. Injecting drug use in low and middle-income countries: opportunities to improve care and prevent harm. J Viral Hepat. 2017 Sep;24(9):714–724. PubMed PMID: 28632952; eng.
   PubMed Web of Science ®Google Scholar
• Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet (London, England). 2008 Nov 15;372(9651):1733–1745. PubMed PMID: 18817968; eng.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017 Dec;5(12):e1192–e1207. PubMed PMID: 29074409; PubMed Central PMCID: PMCPMC5683738. eng.
   PubMed Web of Science ®Google Scholar
• Estrada CR, Suthar AM, Eaton SH, et al. Renal cell carcinoma: children’s hospital Boston experience. Urology. 2005 Dec;66(6):1296–1300. PubMed PMID: 16360460.
   PubMed Web of Science ®Google Scholar
• Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged </=30 years––Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR Morb Mortal Wkly Rep. 2015 May 8;64(17):453–458. PubMed PMID: 25950251; PubMed Central PMCID: PMCPMC4584548. eng.
   PubMed Web of Science ®Google Scholar
• Zibbell JE, Asher AK, Patel RC, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2017 Dec 21:e1–e7. PubMed PMID: 29267061. DOI:10.2105/AJPH.2017.304132
   Web of Science ®Google Scholar
• Burchell AN, Gardner SL, Mazzulli T, et al. Hepatitis C virus seroconversion among HIV-positive men who have sex with men with no history of injection drug use: results from a clinical HIV cohort. Can J Infect Dis Med Microbiol = J Canadien Des Maladies Infectieuses De La Microbiologie Medicale. 2015 Jan-Feb;26(1):17–22. PubMed PMID: 25798149; PubMed Central PMCID: PMCPMC4353264. eng.
   PubMed Web of Science ®Google Scholar
• Lampejo T, Agarwal K, Carey I. Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review. Dig Liver Dis. 2017 Nov 27. PubMed PMID: 29233687. DOI:10.1016/j.dld.2017.11.013
   PubMedGoogle Scholar
• Steininger K, Boyd A, Dupke S, et al. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C. J Viral Hepat. 2017 Oct;24(10):832–839. PubMed PMID: 28439936; eng.
   PubMed Web of Science ®Google Scholar
• Soriano V, Vispo E, Fernandez-Montero JV, et al. Update on HIV/HCV coinfection. Curr HIV/AIDS Rep. 2013 Sep;10(3):226–234. PubMed PMID: 23832718; eng.
   PubMed Web of Science ®Google Scholar
• Joshi D, O’Grady J, Dieterich D, et al. Increasing burden of liver disease in patients with HIV infection. Lancet (London, England). 2011 Apr 2;377(9772):1198–1209. PubMed PMID: 21459211; eng.
   PubMed Web of Science ®Google Scholar
• Boesecke C, Ingiliz P, Reiberger T, et al. Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome. Infection. 2016 Feb;44(1):93–101. PubMed PMID: 26481253; eng.
   PubMed Web of Science ®Google Scholar
• Denniston MM, Klevens RM, McQuillan GM, et al. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology. 2012 Jun;55(6):1652–1661. PubMed PMID: 22213025; PubMed Central PMCID: PMCPMC4586034. eng.
   PubMed Web of Science ®Google Scholar
• European ATNAHCICP. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS treatment network (NEAT) consensus conference. AIDS (London, England). 2011 Feb 20;25(4):399–409. PubMed PMID: 21139491.
   PubMed Web of Science ®Google Scholar
• Larrubia JR, Moreno-Cubero E, Lokhande MU, et al. Adaptive immune response during hepatitis C virus infection. World J Gastroenterol. 2014 Apr 7;20(13):3418–3430. PubMed PMID: 24707125; PubMed Central PMCID: PMCPMC3974509. eng.
   PubMed Web of Science ®Google Scholar
• Shi J, Li Y, Chang W, et al. Current progress in host innate and adaptive immunity against hepatitis C virus infection. Hepatol Int. 2017 Jul;11(4):374–383. PubMed PMID: 28643186; eng.
   PubMed Web of Science ®Google Scholar
• Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol. 2011 Dec;1(6):519–525. PubMed PMID: 22328912; PubMed Central PMCID: PMCPMC3274382. eng.
   PubMed Web of Science ®Google Scholar
• Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol. 2008 May;103(5):1283–97; quiz 1298. PubMed PMID: 18477352; eng.
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Santantonio T, Coppola N, et al. Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment. Infection. 2014 Aug;42(4):601–610. PubMed PMID: 24619833.
   PubMed Web of Science ®Google Scholar
• Boesecke C, Wedemeyer H, Rockstroh JK. Diagnosis and treatment of acute hepatitis C virus infection. Infect Dis Clin North Am. 2012 Dec;26(4):995–1010. PubMed PMID: 23083829.
   PubMed Web of Science ®Google Scholar
• Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006 Jan;13(1):34–41. PubMed PMID: 16364080; eng.
   PubMed Web of Science ®Google Scholar
• Thomson EC, Fleming VM, Main J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut. 2011 Jun;60(6):837–845. PubMed PMID: 21139063; PubMed Central PMCID: PMCPMC3095479. eng.
   PubMed Web of Science ®Google Scholar
• Boesecke C, Muller ME, Nelson M, et al. editor Fueling the epidemic: low rates of spontaneous clearance of acute HCV coinfection. 25th Conference on Retroviruses and Opportunistic Infections; 2018; Boston, Massachusetts, USA.
   Google Scholar
• ClinicalTrials.gov. The Natural History and Treatment of Acute Hepatitis C Virus (HCV) in HIV-positive Individuals (PROBE-C). Bethesda (MD): National Library of Medicine (US); 2011 Feb 3 [cited 2014 Apr 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT01289652?cond=NCT01289652&rank=1
   Google Scholar
• Grebely J, Page K, Sacks-Davis R, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014 Jan;59(1):109–120. PubMed PMID: 23908124; PubMed Central PMCID: PMCPMC3972017. eng.
   PubMed Web of Science ®Google Scholar
• Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. Jama. 2000 Jul 26;284(4):450–456. PubMed PMID: 10904508; eng.
   PubMed Web of Science ®Google Scholar
• Soriano V, Mocroft A, Rockstroh J, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis. 2008 Nov 1;198(9):1337–1344. PubMed PMID: 18767985; eng.
   PubMed Web of Science ®Google Scholar
• Boesecke C, Rockstroh JK. Acute hepatitis C in patients with HIV. Semin Liver Dis. 2012 May;32(2):130–137. PubMed PMID: 22760652.
   PubMed Web of Science ®Google Scholar
• Gilleece YC, Browne RE, Asboe D, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):41–46. PubMed PMID: 16123680; eng.
   PubMed Web of Science ®Google Scholar
• Sharma SA, Feld JJ. Acute hepatitis C: management in the rapidly evolving world of HCV. Curr Gastroenterol Rep. 2014 Feb;16(2):371. PubMed PMID: 24477864.
   PubMedGoogle Scholar
• Tsui JI, Mirzazadeh A, Hahn JA, et al. The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males. Drug Alcohol Depend. 2016 Dec 1;(169):156–162. PubMed PMID: 27816863; PubMed Central PMCID: PMCPMC5328754.
   PubMed Web of Science ®Google Scholar
• Grebely J, Feld JJ, Applegate T, et al. Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology. 2013 Jun;57(6):2124–2134. PubMed PMID: 23325615; PubMed Central PMCID: PMCPMC3663887. eng.
   PubMed Web of Science ®Google Scholar
• Rao HY, Sun DG, Jiang D, et al. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat. 2012 Mar;19(3):173–181. PubMed PMID: 22329371; eng.
   PubMed Web of Science ®Google Scholar
• Beinhardt S, Payer BA, Datz C, et al. A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection. J Hepatol. 2013 Nov;59(5):972–977. PubMed PMID: 23850880; eng.
   PubMed Web of Science ®Google Scholar
• Beinhardt S, Aberle JH, Strasser M, et al. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology. 2012 Jan;142(1):78–85.e2. PubMed PMID: 22192885; eng.
   PubMed Web of Science ®Google Scholar
• Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013 Feb;45(2):164–171. PubMed PMID: 23291588; PubMed Central PMCID: PMCPMC3793390. eng.
   PubMed Web of Science ®Google Scholar
• Cramp ME, Carucci P, Underhill J, et al. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol. 1998 Aug;29(2):207–213. PubMed PMID: 9722201; eng.
   PubMed Web of Science ®Google Scholar
• Vogel M, Page E, Matthews G, et al. editors. Use of week 4 HCV RNA after acute HCV infection to predict chronic HCV infection. 17th Conference on Retroviruses and Opportunistic Infections; 2010; San Francisco, California, USA.
   Google Scholar
• Santantonio T, Fasano M, Sinisi E, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol. 2005 Mar;42(3):329–333. PubMed PMID: 15710214; eng.
   PubMed Web of Science ®Google Scholar
• Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001 Nov 15;345(20):1452–1457. PubMed PMID: 11794193; eng.
   PubMed Web of Science ®Google Scholar
• Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006 Feb;43(2):250–256. PubMed PMID: 16440367; eng.
   PubMed Web of Science ®Google Scholar
• Bethea E, Chen Q, Hur C, et al. Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology. 2017 Oct 23. PubMed PMID: 29059461. DOI:10.1002/hep.29611
   PubMedGoogle Scholar
• Martin NK, Thornton A, Hickman M, et al. Can hepatitis C virus (HCV) direct-acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights. Clin Infect Dis. 2016 May 1;62(9):1072–1080. PubMed PMID: 26908813; PubMed Central PMCID: PMCPMC4826456. eng.
   PubMed Web of Science ®Google Scholar
• Boerekamps A, van den Berk GE, Lauw FN, et al. Substantial decline in acute HCV infections among Dutch HIV+MSM after DAA roll out. Conference on Retroviruses adn Opportunistic Infections; 2017 Feb 13-16; Seattle, WA.
   Google Scholar
• Zampino R, Coppola N, Sagnelli C, et al. Hepatitis C virus infection and prisoners: epidemiology, outcome and treatment. World J Hepatol. 2015 Sep 28;7(21):2323–2330. PubMed PMID: 26413221; PubMed Central PMCID: PMCPMC4577639. eng.
   PubMedGoogle Scholar
• Pungle P, Banavalikar M, Suthar A, et al. Immunomodulatory activity of boswellic acids of Boswellia serrata Roxb. Indian J Exp Biol. 2003 Dec;41(12):1460–1462. PubMed PMID: 15320503.
   PubMedGoogle Scholar
• He T, Li K, Roberts MS, et al. Prevention of hepatitis C by screening and treatment in U.S. Prisons. Ann Intern Med. 2016 Jan 19;164(2):84–92. PubMed PMID: 26595252; PubMed Central PMCID: PMCPMC4854298. eng.
   PubMed Web of Science ®Google Scholar
• Dolan K, Teutsch S, Scheuer N, et al. Incidence and risk for acute hepatitis C infection during imprisonment in Australia. Eur J Epidemiol. 2010 Feb;25(2):143–148. PubMed PMID: 20084429; eng.
   PubMed Web of Science ®Google Scholar
• Teutsch S, Luciani F, Scheuer N, et al. Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health. 2010 Oct 22;(10):633. PubMed PMID: 20964864; PubMed Central PMCID: PMCPMC2975656. eng.
   PubMed Web of Science ®Google Scholar
• Deterding K, Gruner N, Buggisch P, et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis. 2013 Jun;13(6):497–506. PubMed PMID: 23523674; eng.
   PubMed Web of Science ®Google Scholar
• Santantonio T, Fasano M, Sagnelli E, et al. Acute hepatitis C: a 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin. Hepatology. 2014 Jun;59(6):2101–2109. PubMed PMID: 24442928.
   PubMed Web of Science ®Google Scholar
• Zhang B, Nguyen NH, Yee BE, et al. Treatment of acute hepatitis C infection with pegylated interferon and ribavirin in patients coinfected with human immunodeficiency virus: a systematic review and meta-analysis. Intervirology. 2015;58(4):242–249. PubMed PMID: 26402746.
   PubMed Web of Science ®Google Scholar
• Matthews GV, Hellard M, Haber P, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian trial in acute hepatitis C. Clin Infect Dis. 2009 Mar 1;48(5):650–658. PubMed PMID: 19191653; PubMed Central PMCID: PMCPMC2895679. eng.
   PubMed Web of Science ®Google Scholar
• Deterding K, Grüner N, Wiegand J, et al. 1047 EARLY VERSUS DELAYED TREATMENT OF ACUTE HEPATITIS C: THE GERMAN HEP-NET ACUTE HCV-III STUDY–A RANDOMIZED CONTROLLED TRIAL. J Hepatol. 2009;50:S380.
   Google Scholar
• Matthews G, Grebely J, Hellard M, et al. editors. Differences in early virological decline in individuals treated within the Australian trial in acute HCV suggest a potential benefit for the use of ribavirin. J Hepatol. 2010;52:S28. ELSEVIER SCIENCE BV PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS.
   PubMed Web of Science ®Google Scholar
• Basu P, Shah NJ, John N, et al. Sofosbuvir and ledipasvir versus sofosbuvir and simeprevir combination therapy in the management of acute hepatitis C: a randomized open label prospective clinical pilot study. SLAM C study. Interim data. Hepatology. 2015;62:736A.
   Google Scholar
• Deterding K, Spinner CD, Schott E, et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis. 2017 Feb;17(2):215–222. PubMed PMID: 28029529; eng.
   PubMed Web of Science ®Google Scholar
• EACS. EACS Guidelines version 9.0. Brussels (Belgium): European AIDS Clinical Society; 2017 [cited Mar 10]. Available from: http://www.eacsociety.org/files/guidelines_9.0-english.pdf
   Google Scholar
• Brancaccio G, Sorbo MC, Frigeri F, et al. Treatment of acute hepatitis C with ledipasvir and sofosbuvir in patients with hematological malignancies allows early re-start of chemotherapy. Clin Gastroenterol Hepatol. 2017 Nov 28. PubMed PMID: 29104131; eng. DOI:10.1016/j.cgh.2017.10.032
   PubMed Web of Science ®Google Scholar
• Hullegie SJ, Claassen MA, van den Berk GE, et al. Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients. J Hepatol. 2016 Apr;64(4):807–812. PubMed PMID: 26689767; eng.
   PubMed Web of Science ®Google Scholar
• Fierer DS, Dieterich DT, Mullen MP, et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis. 2014 Mar;58(6):873–879. PubMed PMID: 24336914; PubMed Central PMCID: PMCPMC3935497. eng.
   PubMed Web of Science ®Google Scholar
• Boesecke C, Singh GKJ, Scholten SH, et al. Telaprevir-containing triple therapy in acute HCV coinfection: the CHAT study. Antivir Ther. 2017;22(7):619–623. PubMed PMID: 28240597; eng.
   PubMed Web of Science ®Google Scholar
• Martinello M, Gane E, Hellard M, et al. Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: the DARE-C II study. Hepatology. 2016 Dec;64(6):1911–1921. PubMed PMID: 27639183; eng.
   PubMed Web of Science ®Google Scholar
• Naggie S, Marks KM, Hughes M, et al. Sofosbuvir plus ribavirin without interferon for treatment of acute hepatitis C virus infection in HIV-1-infected individuals: SWIFT-C. Clin Infect Dis. 2017 Apr 15;64(8):1035–1042. PubMed PMID: 28329053.
   PubMed Web of Science ®Google Scholar
• El Sayed A, Barbati ZR, Turner SS, et al. Sofosbuvir in the treatment of early HCV infection in HIV-infected men. HIV Clinical Trials. 2017 Mar;18(2):60–66. PubMed PMID: 28183221; eng.
   PubMed Web of Science ®Google Scholar
• Wu L-S, Wang H, Geng X-P. Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis. Exp Ther Med. 2012;3(2):200–206.
   PubMed Web of Science ®Google Scholar
• Morales-Vasquez L, Miranda-Avalo EI, Rodriguez-Medina JR, et al. Demographics, clinical characteristics, IFNL3- and IFNL4- polymorphisms in a cohort of hepatitis C patients from Puerto Rico. P R Health Sci J. 2014 Dec;33(4):177–183. PubMed PMID: 25563035; PubMed Central PMCID: PMCPMC4337961. eng.
   PubMed Web of Science ®Google Scholar
• Ito J, Suda G, Yamamoto Y, et al. Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection. Hepatol Res. 2016 Dec;46(13):1294–1303. PubMed PMID: 26896756; eng.
   PubMed Web of Science ®Google Scholar
• Osinusi A, Meissner EG, Lee Y-J, et al. Efficacy of sofosbuvir and ribavirin for treatment of hepatitis C genotype-1 in an inner city population: virus and host factors that predict relapse: a randomized controlled trial. JAMA. 2013;310(8):804.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. New England J Med. 2013;368(1):34–44.
   PubMed Web of Science ®Google Scholar
• Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31;373(27):2608–2617. PubMed PMID: 26575258; eng.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Bhagani S, Hyland RH, et al. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2017 May;2(5):347–353. PubMed PMID: 28397698.
   PubMed Web of Science ®Google Scholar
• Fierer D, El Sayed A, Palaniswami P. Treatment of “acute” hepatitis C virus in human immunodeficiency virus-infected men with short-course sofosbuvir/ledipasvir. J Hepatol. 2017;66(1):S300.
   Web of Science ®Google Scholar
• Naggie S, Fierer DS, Hughes M, et al. editors. 100% SVR with 8 weeks of ledipasvir/sofosbuvir in HIV-infected men with acute HCV infection: results from the SWIFT-C trial (sofosbuvir-containing regimens without interferon for treatment of acute HCV in HIV-1 infected individuals). Hepatology. 2017. 66: Page 113A-113A WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
   PubMedGoogle Scholar
• European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017 Jan;66(1):153–194. PubMed PMID: 27667367; eng.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015 Dec 31;373(27):2599–2607. PubMed PMID: 26571066; eng.
   PubMed Web of Science ®Google Scholar
• Mir F, Kahveci AS, Ibdah JA, et al. Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure. Drug Des Devel Ther. 2017;11:497–502. PubMed PMID: 28260862; PubMed Central PMCID: PMCPMC5330188. eng.
   PubMed Web of Science ®Google Scholar
• Bunchorntavakul C, Reddy KR. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2015 Aug;42(3):258–272. PubMed PMID: 26014906; eng.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV (DAHHS-2). Bethesda (MD): National Library of Medicine (US); 2015 Nov 5 [cited 2018 Feb 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT02600325
   Google Scholar
• ClinicalTrials.gov. Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4 in HIV-infected Patients (SAHIV). Bethesda (MD): National Library of Medicine (US); 2016 Aug 29 [cited 2017 Jul 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02886624
   Google Scholar
• ClinicalTrials.gov. Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection. (REACT). Bethesda (MD): National Library of Medicine (US); 2015 Dec 7[cited 2017 Sept 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT02625909
   Google Scholar
• ClinicalTrials.gov. Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P (TARGET3D). Bethesda (MD): National Library of Medicine (US); 2018 Jan 30 [updated 2015 Dec 30; cited 2015 Jan 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02634008
   Google Scholar
• Puoti M, Foster GR, Wang S, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir: integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol. 2018 Mar 15;69:293–300. PubMed PMID: 29551706; eng.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Integrating HCV and HIV Screening During the Era of HIV Antigen Testing. Bethesda (MD): National Library of Medicine (US); 2016 Aug 10 [cited 2017 Aug 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02869776?cond=NCT02869776&rank=1
   Google Scholar
• ClinicalTrials.gov. Integrating HIV and Hepatitis C Screening in an Urban Emergency Department. Bethesda (MD): National Library of Medicine (US). 2017 July 28 [cited 2017 Aug 17]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03252483
   Google Scholar
• Patel EU, Cox AL, Mehta SH, et al. Use of hepatitis C virus (HCV) immunoglobulin g antibody avidity as a biomarker to estimate the population-level incidence of HCV infection. J Infect Dis. 2016 Aug 1;214(3):344–352. PubMed PMID: 26768250; PubMed Central PMCID: PMCPMC4936640. eng.
   PubMed Web of Science ®Google Scholar